PepGen Ltd Cash Flow Conversion Efficiency
PepGen Ltd cash flow conversion efficiency. Based on the latest financial reports, PepGen Ltd (PEPG) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.81 Million) by net assets ($119.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PepGen Ltd (2019–2025)
Cash flow conversion efficiency of PepGen Ltd from 2019 to 2025. This chart illustrates how PepGen Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PEPG stock price for real-time trading data and today's change.
PepGen Ltd Cash Flow Conversion Ratio Explained
PepGen Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PepGen Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PepGen Ltd ranked by their cash flow conversion efficiency. Also see PepGen Ltd (PEPG) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
0.013x |
|
OMS Energy Technologies Inc.
NASDAQ:OMSE
|
0.023x |
|
Bonterra Energy Corp
TO:BNE
|
0.086x |
|
Lippo Karawaci Tbk
JK:LPKR
|
-0.016x |
|
MEDICLIN Aktiengesellschaft
XETRA:MED
|
0.097x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
|
HMS Bergbau AG
XETRA:HMU
|
-0.399x |
|
Asara Resources Ltd
AU:AS1
|
-0.027x |
Annual Cash Flow Conversion Efficiency for PepGen Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of PepGen Ltd from 2019 to 2025. Review PEPG FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.44 Million | $-81.64 Million | -0.554x | +20.27% |
| 2024-12-31 | $118.62 Million | $-82.37 Million | -0.694x | -9.12% |
| 2023-12-31 | $108.42 Million | $-69.00 Million | -0.636x | -92.89% |
| 2022-12-31 | $179.63 Million | $-59.27 Million | -0.330x | -94.31% |
| 2021-12-31 | $133.09 Million | $-22.60 Million | -0.170x | -0.46% |
| 2020-12-31 | $9.77 Million | $-1.65 Million | -0.169x | +26.15% |
| 2019-12-31 | $3.87 Million | $-885.00K | -0.229x | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more